DelveInsight预测，到2032年，注意力缺陷/多动障碍市场将快速增长|市场上的主要公司-Cingulate、Otsuka、Supernus、Neurocentria、ABVC BioPharma、Axsome、BioLite、Mind Medicine-动脉网

Attention-Deficit/Hyperactivity Disorder Market to Grow Rapidly by 2032, Predicts DelveInsight | Key Companies in the Market - Cingulate, Otsuka, Supernus, Neurocentria, ABVC BioPharma, Axsome, BioLite, Mind Medicine

CISION 等信源发布 2023-09-12 00:01



可切换为仅中文







The dynamics of the attention-deficit/hyperactivity disorder market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies

由于诊断方法的改进，对该疾病的认识不断提高，全球医疗保健支出的增加以及预期的新兴疗法的推出，注意力缺陷/多动障碍市场的动态预计将在未来几年发生变化

LAS VEGAS, Sept. 11, 2023 /PRNewswire/ -- DelveInsight's Attention-Deficit/Hyperactivity Disorder Market Insights report includes a comprehensive understanding of current treatment practices, attention-deficit/hyperactivity disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]..

拉斯维加斯，2023年9月11日/PRNewswire/-DelveInsight的注意力缺陷/多动障碍市场洞察力报告包括对当前治疗实践，注意力缺陷/多动障碍新兴药物，个体治疗市场份额以及当前和预测的全面了解2019年至2032年的市场规模，分为7MM[美国，EU-4（意大利，西班牙，法国和德国），英国和日本]）。。

Key Takeaways from the Attention-Deficit/Hyperactivity Disorder Market Report

注意力缺陷/多动障碍市场报告的主要收获

According to DelveInsight analysis, the attention-deficit/hyperactivity disorder market is anticipated to surge at a significant CAGR by 2032.

根据DelveInsight分析，到2032年，注意力缺陷/多动障碍市场预计将以显着的CAGR飙升。

ADHD is more common in males than females and females with ADHD are more likely to have problems primarily with inattention.

多动症在男性中比女性更常见，患有多动症的女性更容易出现主要注意力不集中的问题。

Globally, leading attention-deficit/hyperactivity disorder companies such as Cingulate Therapeutics, Otsuka Pharmaceutical, Supernus Pharmaceuticals, Inc., Neurocentria, Inc., ABVC BioPharma, Inc, Axsome Therapeutics, Inc., BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals, KemPharm, Arbor Pharmaceuticals, Ensysce Biosciences, NLS Pharmaceutics, 3Z Pharmaceuticals, and others are developing novel attention-deficit/hyperactivity disorder drugs that can be available in the attention-deficit/hyperactivity disorder market in the coming years..

在全球范围内，领先的注意力缺陷/多动障碍公司，例如Cingulate Therapeutics，大冢制药，Supernus Pharmaceuticals，Inc.，Neurocentria，Inc.，ABVC BioPharma，Inc.，Axsome Therapeutics，Inc.，BioLite，Mind Medicine，Tris Pharma，RespireRx Pharmaceuticals，KemPharm，Arbor Pharmaceuticals，Ensysce Biosciences，NLS Pharmaceutics，3Z Pharmaceuticals，和其他人正在开发新的注意力缺陷/多动障碍药物，这些药物可在未来几年的注意力缺陷/多动障碍市场中获得。。

Some key therapies for attention-deficit/hyperactivity disorder treatment include Centanafadine capsule, CTx-1301 - Dexmethylphenidate, SPN-812, NRCT-101-SR, PDC-1421, Solriamfetol, and others.

注意力缺陷/多动障碍治疗的一些关键疗法包括Centanafadine胶囊，CTx-1301-右哌甲酯，SPN-812，NRCT-101-SR，PDC-1421，Solriamfetol等。

Discover which therapies are expected to grab the major attention-deficit/hyperactivity disorder market share @ Attention-Deficit/Hyperactivity Disorder Market Report

发现哪些疗法有望抓住主要的注意力缺陷/多动障碍市场份额@注意力缺陷/多动障碍市场报告

Attention-Deficit/Hyperactivity Disorder Overview

注意缺陷/多动障碍概述

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects both children and adults, though it often manifests during childhood. Its exact causes remain a subject of ongoing research, but a combination of genetic, environmental, and neurological factors is believed to contribute to its development.

注意力缺陷/多动障碍（ADHD）是一种影响儿童和成人的神经发育障碍，尽管它通常在儿童时期表现出来。其确切原因仍然是正在进行的研究的主题，但是遗传，环境和神经因素的组合被认为有助于其发展。

The hallmark symptoms of ADHD include inattention, hyperactivity, and impulsivity. Inattentive symptoms often manifest as difficulty focusing, forgetfulness, careless mistakes, and organizational challenges. Hyperactivity symptoms involve excessive fidgeting, restlessness, and difficulty staying seated or quiet when necessary.

ADHD的标志性症状包括注意力不集中，活动过度和冲动。注意力不集中的症状通常表现为注意力不集中，健忘，粗心的错误和组织挑战。多动症状包括过度烦躁，烦躁不安，必要时难以保持坐姿或安静。

Impulsivity leads to hasty decisions, interrupting others, and difficulty waiting one's turn. These symptoms can impact academic performance, relationships, and daily functioning. Diagnosing ADHD requires a comprehensive evaluation by a qualified healthcare professional. Criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) are typically used.

冲动导致匆忙的决定，打断他人，难以等待转弯。这些症状会影响学习成绩，人际关系和日常功能。诊断ADHD需要由合格的医疗保健专业人员进行全面评估。通常使用《精神疾病诊断和统计手册》（DSM-5）中的标准。

This process involves gathering information from various sources, including parents, teachers, and the individual..

此过程涉及从各种来源（包括父母，老师和个人）收集信息。。

Attention-Deficit/Hyperactivity Disorder Epidemiology Segmentation

注意缺陷/多动障碍流行病学细分

The attention-deficit/hyperactivity disorder epidemiology section provides insights into the historical and current attention-deficit/hyperactivity disorder patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. .

注意力缺陷/多动障碍流行病学部分提供了有关历史和当前注意力缺陷/多动障碍患者库以及七个主要国家的预测趋势的见解。它通过探索众多研究和主要意见领袖的观点，有助于认识当前和预测趋势的原因。 .

The attention-deficit/hyperactivity disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

注意缺陷/多动障碍市场报告提供了2019-2032年研究期间的流行病学分析，其中7MM分为：

Total ADHD Diagnosed Prevalent Cases

总ADHD诊断流行病例

ADHD Gender-specific Diagnosed Prevalent Cases

多动症性别特异性诊断流行病例

ADHD Gender-specific Diagnosed Prevalent Cases

多动症性别特异性诊断流行病例

ADHD Subtype-specific Diagnosed Prevalent Cases

ADHD亚型特异性诊断流行病例

Attention-Deficit/Hyperactivity Disorder Treatment Market

注意缺陷/多动障碍治疗市场

The ADHD treatment is a multifaceted approach aimed at managing its symptoms and improving overall functioning. It typically involves a combination of behavioral interventions, psychotherapy, and, in some cases, medication. Behavioral interventions, such as cognitive-behavioral therapy (CBT) and parent training, help individuals with ADHD develop coping strategies and improve their organizational skills.

ADHD治疗是一种多方面的方法，旨在管理其症状和改善整体功能。它通常涉及行为干预，心理治疗以及在某些情况下药物治疗的组合。行为干预，如认知行为疗法（CBT）和家长培训，帮助ADHD患者制定应对策略并提高他们的组织技能。

Psychoeducation is also a crucial aspect, ensuring that individuals and their families understand the nature of ADHD and its impact. Medications like stimulants (e.g., methylphenidate) and non-stimulants (e.g., atomoxetine) may be prescribed when symptoms significantly impair daily life. Treatment plans are often individualized to address specific needs and can evolve over time.

心理教育也是一个关键方面，确保个人及其家属了解ADHD的性质及其影响。当症状显着损害日常生活时，可以开出诸如兴奋剂（例如哌醋甲酯）和非兴奋剂（例如阿托西汀）的药物。治疗计划通常是个性化的，以满足特定的需求，并可能随着时间的推移而发展。

With proper diagnosis and ongoing support, individuals with ADHD can learn to manage their symptoms effectively and lead fulfilling lives..

通过适当的诊断和持续的支持，ADHD患者可以学会有效地管理他们的症状并过上充实的生活。。

Certainly, the comprehensive treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) also encompasses lifestyle modifications and support systems. These adjustments may include creating a structured daily routine, setting up reminders and alarms, and breaking tasks into smaller, more manageable steps.

当然，注意力缺陷/多动障碍（ADHD）的综合治疗也包括生活方式的改变和支持系统。这些调整可能包括创建结构化的日常例程，设置提醒和警报，以及将任务分解为更小，更易于管理的步骤。

Regular exercise, a balanced diet, and adequate sleep play pivotal roles in managing ADHD symptoms, as they help regulate mood and concentration. Moreover, a strong support network is crucial. This often involves family members, teachers, and mental health professionals working together to provide consistent guidance and encouragement.

定期运动，均衡饮食和充足的睡眠在控制ADHD症状中起着关键作用，因为它们有助于调节情绪和注意力。而且，强大的支持网络至关重要。这通常涉及家庭成员，教师和心理健康专业人员共同努力，提供一致的指导和鼓励。

Educators can adapt teaching strategies to accommodate the learning style of students with ADHD, while employers can offer workplace accommodations when necessary..

教育工作者可以调整教学策略，以适应ADHD学生的学习风格，而雇主可以在必要时提供工作场所住宿。。

To know more about attention-deficit/hyperactivity disorder treatment, visit @ ADHD Treatment Drugs

要了解更多关于注意力缺陷/多动障碍治疗的信息，请访问@ADHD治疗药物

Key Attention-Deficit/Hyperactivity Disorder Therapies and Companies

关键注意力缺陷/多动障碍疗法和公司

Centanafadine capsule: Otsuka Pharmaceutical Development & Commercialization, Inc.

Centanafadine胶囊：大冢制药开发与商业化公司。

CTx-1301 - Dexmethylphenidate: Cingulate Therapeutics

CTx-1301-Dexmethylphenidate：Cingulate Therapeutics

SPN-812: Supernus Pharmaceuticals, Inc.

SPN-812：Supernus Pharmaceuticals，股份有限公司。

NRCT-101-SR: Neurocentria, Inc.

NRCT-101-SR：神经中枢，公司。

PDC-1421: BioLite, Inc./ABVC BioPharma, Inc

PDC-1421:BioLite，股份有限公司/ABVC BioPharma，股份有限公司。

Solriamfetol: Axsome Therapeutics, Inc.

Solriamfetol:Axsome Therapeutics，Inc。

Learn more about the FDA-approved drugs for ADHD @ Drugs for Attention-Deficit/Hyperactivity Disorder Treatment

了解更多关于FDA批准的ADHD@药物治疗注意力缺陷/多动障碍的药物

Attention-Deficit/Hyperactivity Disorder Market Dynamics

注意缺陷/多动障碍市场动态

The ADHD market dynamics have been evolving in response to a growing understanding of the disorder and changes in diagnostic criteria. With an increasing awareness of ADHD, there has been a notable expansion in the ADHD market for pharmaceuticals, therapy, and educational interventions tailored to manage its symptoms.

随着对疾病的日益了解和诊断标准的变化，ADHD市场动态一直在发展。随着人们对ADHD的认识不断提高，ADHD市场的药物，治疗和针对其症状的教育干预措施显着扩大。

Pharmaceutical companies are continually innovating to develop more effective and targeted medications, such as extended-release formulations, which offer convenience and sustained symptom relief. .

制药公司不断创新，开发更有效和更有针对性的药物，如缓释制剂，提供便利和持续的症状缓解。 .

Additionally, the rise of telemedicine and digital health solutions has transformed the way individuals access ADHD diagnosis and treatment, offering greater convenience and accessibility. The ADHD market also reflects a growing demand for holistic approaches to managing ADHD, including behavioral therapy and lifestyle modifications, as more individuals seek comprehensive, long-term solutions beyond medication alone.

此外，远程医疗和数字健康解决方案的兴起改变了个人获得ADHD诊断和治疗的方式，提供了更大的便利性和可及性。ADHD市场也反映了对管理ADHD的整体方法的需求不断增长，包括行为疗法和生活方式的改变，因为越来越多的人寻求除药物治疗之外的全面，长期的解决方案。

These evolving dynamics demonstrate a broader recognition of the multifaceted nature of ADHD and the need for tailored patient-centric care strategies..

这些不断发展的动态表明，人们对ADHD的多方面性质以及对量身定制的以患者为中心的护理策略的需求有了更广泛的认识。。

Despite the evolving ADHD market dynamics, several significant barriers persist. One of the primary challenges is the stigma associated with ADHD, which can lead to underdiagnosis and undertreatment. Many individuals, especially adults, may be hesitant to seek help due to concerns about being labeled or misunderstood.

尽管ADHD市场动态不断发展，但仍存在一些重大障碍。主要挑战之一是与ADHD相关的耻辱感，这可能导致诊断不足和治疗不足。由于担心被贴上标签或误解，许多人，特别是成年人，可能会犹豫寻求帮助。

Another critical barrier is the high cost associated with ADHD diagnosis and management. Access to comprehensive assessment, medication, therapy, and educational support can be expensive, especially for individuals without adequate health insurance coverage. This financial burden can limit access to essential services, particularly for marginalized communities..

另一个关键障碍是与ADHD诊断和管理相关的高成本。获得全面评估，药物治疗和教育支持的机会可能很昂贵，特别是对于没有足够医疗保险的个人。这种经济负担可能会限制获得基本服务，特别是对于边缘化社区。。

Additionally, there's a shortage of qualified healthcare professionals and therapists with expertise in ADHD, leading to long waiting times for diagnosis and treatment. This can be especially problematic for children whose academic and social development can be significantly impacted by delayed intervention.

此外，缺乏具有ADHD专业知识的合格医疗保健专业人员和治疗师，导致诊断和治疗的等待时间很长。这对于延迟干预可能对学术和社会发展产生重大影响的儿童尤其成问题。

Moreover, the overdiagnosis and overmedication of ADHD, particularly among children, is a concern. Misdiagnosis can lead to unnecessary pharmaceutical interventions, potentially subjecting individuals to side effects without addressing the underlying issues accurately..

此外，ADHD的过度诊断和过度用药，特别是儿童，是一个值得关注的问题。误诊可能导致不必要的药物干预，可能使个体遭受副作用而无法准确解决潜在问题。。

Report Metrics

报告指标

Details

细节

Study Period

学习期

2019–2032

Coverage

新闻报道

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

7MM[美国、欧盟4国（德国、法国、意大利和西班牙）、英国和日本]

Key Attention-Deficit/Hyperactivity Disorder Companies

主要注意力缺陷/多动障碍公司

Cingulate Therapeutics, Otsuka Pharmaceutical, Supernus Pharmaceuticals, Inc., Neurocentria, Inc., ABVC BioPharma, Inc, Axsome Therapeutics, Inc., BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals, KemPharm, Arbor Pharmaceuticals, Ensysce Biosciences, NLS Pharmaceutics, 3Z Pharmaceuticals, and others .

Cingulate Therapeutics，Otsuka Pharmaceutical，Supernus Pharmaceuticals，Inc.，Neurocentria，Inc.，ABVC BioPharma，Inc，Axsome Therapeutics，Inc.，BioLite，Mind Medicine，Tris Pharma，RespireRx Pharmaceuticals，KemPharm，Arbor Pharmaceuticals，Ensysce Biosciences，NLS Pharmaceutics，3Z制药等。

Key Attention-Deficit/Hyperactivity Disorder Therapies

关键注意缺陷/多动障碍疗法

Centanafadine capsule, CTx-1301 - Dexmethylphenidate, SPN-812, NRCT-101-SR, PDC-1421, Solriamfetol, and others

Centanafadine capsule，CTx-1301-Dexmethylphenidate，SPN-812，NRCT-101-SR，PDC-1421，Solriamfetol等

Scope of the Attention-Deficit/Hyperactivity Disorder Market Report

注意缺陷/多动障碍市场报告的范围

Therapeutic Assessment: Attention-Deficit/Hyperactivity Disorder current marketed and emerging therapies

治疗评估：注意力缺陷/多动障碍当前上市和新兴疗法

Attention-Deficit/Hyperactivity Disorder Market Dynamics: Conjoint Analysis of Emerging Attention-Deficit/Hyperactivity Disorder Drugs

注意缺陷/多动障碍市场动态：新兴注意缺陷/多动障碍药物的联合分析

Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

竞争智力分析：SWOT分析和市场准入策略

Unmet Needs, KOL's views, Analyst's views, Attention-Deficit/Hyperactivity Disorder Market Access and Reimbursement

未满足的需求，科尔的观点，分析师的观点，注意力缺陷/多动障碍的市场准入和报销

Discover more about ADHD drugs in development @ ADHD Clinical Trials

更多关于ADHD药物开发@ADHD临床试验

Table of Contents

Attention-Deficit/Hyperactivity Disorder Market Key Insights

注意缺陷/多动障碍市场关键见解

Attention-Deficit/Hyperactivity Disorder Market Report Introduction

注意缺陷/多动障碍市场报告简介

Attention-Deficit/Hyperactivity Disorder Market Overview at a Glance

注意缺陷/多动障碍市场概况一目了然

Attention-Deficit/Hyperactivity Disorder Market Executive Summary

注意缺陷/多动障碍市场执行摘要

Disease Background and Overview

疾病背景和概述

Attention-Deficit/Hyperactivity Disorder Treatment and Management

注意缺陷/多动障碍的治疗和管理

Attention-Deficit/Hyperactivity Disorder Epidemiology and Patient Population

注意缺陷/多动障碍流行病学和患者人群

Patient Journey

耐心之旅

Attention-Deficit/Hyperactivity Disorder Marketed Drugs

注意缺陷/多动障碍销售药物

10.

Attention-Deficit/Hyperactivity Disorder Emerging Drugs

注意缺陷/多动障碍新兴药物

11.

Seven Major Attention-Deficit/Hyperactivity Disorder Market Analysis

七大注意力缺陷/多动障碍市场分析

12.

Attention-Deficit/Hyperactivity Disorder Market Outlook

注意缺陷/多动障碍市场前景

13.

Potential of Current and Emerging Therapies

当前和新兴疗法的潜力

14.

KOL Views

15.

Unmet Needs

未满足的需求

16.

SWOT Analysis

SWOT分析

17.

Appendix

附录

18.

DelveInsight Capabilities

DelveInsight功能

19.

Disclaimer

免责声明

20.

About DelveInsight

关于DelveInsight

Related Reports